Dean A Fennell1, Paul Baas2, Paul Taylor3, Anna K Nowak4, David Gilligan5, Takashi Nakano6, Jonathan A Pachter7, David T Weaver7, Arnaud Scherpereel8, Nick Pavlakis9, Jan P van Meerbeeck10, Susana Cedrés11, Luke Nolan12, Hedy Kindler13, Joachim G J V Aerts14. 1. 1 University of Leicester, Leicester, United Kingdom. 2. 2 Netherlands Cancer Institute, Amsterdam, the Netherlands. 3. 3 Wythenshawe Hospital, Manchester, United Kingdom. 4. 4 University of Western Australia and Sir Charles Gairdner Hospital, Perth, WA, Australia. 5. 5 Cambridge University Hospitals National Health Service Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom. 6. 6 Hyogo College of Medicine, Hyogo, Japan. 7. 7 Verastem, Boston, MA. 8. 8 Calmette Hospital, Regional University Hospital of Lille, Lille Cedex, France. 9. 9 Northern Cancer Institute, St Leonards, NSW, Australia. 10. 10 Universitair Ziekenuis, Antwerp, Belgium. 11. 11 Karolinska University Hospital, Stockholm, Sweden. 12. 12 University Hospital, Southampton, United Kingdom. 13. 13 University of Chicago Medical Center, Chicago, IL. 14. 14 Erasmus Medical College, Rotterdam, the Netherlands.
Abstract
PURPOSE: Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that express low levels of moesin-ezrin-radixin-like protein (merlin). On this basis, we designed a randomized, phase II trial to investigate whether defactinib as maintenance therapy after standard first-line chemotherapy could improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM). METHODS: This global, double-blind, randomized, placebo-controlled trial was conducted in patients with advanced MPM and disease control after at least four cycles of first-line chemotherapy. Patients were stratified for merlin and then randomly assigned (in a 1:1 fashion) to receive either oral defactinib or placebo until disease progression, unacceptable toxicity, or withdrawal occurred. The coprimary end points were PFS and overall survival (OS). Quality of life (QoL) was assessed using the Lung Cancer Symptom Scale for Mesothelioma tool. RESULTS:Three hundred forty-four patients were randomly assigned to receive either defactinib (n = 173) or placebo (n = 171). The median PFS was 4.1 months (95% CI, 2.9 to 5.6 months) for defactinib versus 4.0 months (95% CI, 2.9 to 4.2 months) for placebo. The median OS was 12.7 months (95% CI, 9.1 to 21 months) for defactinib versus 13.6 months (95% CI, 9.6 to 21.2 months) for placebo (hazard ratio, 1.0; 95% CI, 0.7 to 1.4). Although shorter survival for both defactinib- and placebo-treated patients was observed, in the patients who had merlin-low MPM compared with the patients who had merlin-high MPM, there were no statistical differences in response rate, PFS, OS, or QoL between the treatment groups. The most common grade 3 or worse adverse events were nausea, diarrhea, fatigue, dyspnea, and decreased appetite. CONCLUSION: Neither PFS nor OS was improved by defactinib after first-line chemotherapy in patients with merlin-low MPM. Defactinib cannot be recommended as maintenance therapy for advanced MPM.
RCT Entities:
PURPOSE: Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that express low levels of moesin-ezrin-radixin-like protein (merlin). On this basis, we designed a randomized, phase II trial to investigate whether defactinib as maintenance therapy after standard first-line chemotherapy could improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM). METHODS: This global, double-blind, randomized, placebo-controlled trial was conducted in patients with advanced MPM and disease control after at least four cycles of first-line chemotherapy. Patients were stratified for merlin and then randomly assigned (in a 1:1 fashion) to receive either oral defactinib or placebo until disease progression, unacceptable toxicity, or withdrawal occurred. The coprimary end points were PFS and overall survival (OS). Quality of life (QoL) was assessed using the Lung Cancer Symptom Scale for Mesothelioma tool. RESULTS: Three hundred forty-four patients were randomly assigned to receive either defactinib (n = 173) or placebo (n = 171). The median PFS was 4.1 months (95% CI, 2.9 to 5.6 months) for defactinib versus 4.0 months (95% CI, 2.9 to 4.2 months) for placebo. The median OS was 12.7 months (95% CI, 9.1 to 21 months) for defactinib versus 13.6 months (95% CI, 9.6 to 21.2 months) for placebo (hazard ratio, 1.0; 95% CI, 0.7 to 1.4). Although shorter survival for both defactinib- and placebo-treated patients was observed, in the patients who had merlin-low MPM compared with the patients who had merlin-high MPM, there were no statistical differences in response rate, PFS, OS, or QoL between the treatment groups. The most common grade 3 or worse adverse events were nausea, diarrhea, fatigue, dyspnea, and decreased appetite. CONCLUSION: Neither PFS nor OS was improved by defactinib after first-line chemotherapy in patients with merlin-low MPM. Defactinib cannot be recommended as maintenance therapy for advanced MPM.
Authors: Anand Singh; Nisan Bhattacharyya; Abhishek Srivastava; Nathanael Pruett; R Taylor Ripley; David S Schrump; Chuong D Hoang Journal: Mol Ther Date: 2019-06-04 Impact factor: 11.454
Authors: Arkadiusz Z Dudek; Xiaofei Wang; Lin Gu; Stephanie Duong; Thomas E Stinchcombe; Robert Kratzke; Hossein Borghaei; Everett E Vokes; Hedy L Kindler Journal: Clin Lung Cancer Date: 2020-07-03 Impact factor: 4.785
Authors: David E Gerber; D Ross Camidge; Daniel Morgensztern; Jeremey Cetnar; Ronan J Kelly; Suresh S Ramalingam; David R Spigel; Woondong Jeong; Pier P Scaglioni; Song Zhang; Marilyn Li; David T Weaver; Louis Vaikus; Mitchell Keegan; Joanna C Horobin; Timothy F Burns Journal: Lung Cancer Date: 2019-11-04 Impact factor: 5.705
Authors: Christine E Lehman; Adam Spencer; Sarah Hall; Jeremy J P Shaw; Julia Wulfkuhle; Emanuel F Petricoin; Stefan Bekiranov; Mark J Jameson; Daniel Gioeli Journal: Sci Rep Date: 2021-05-24 Impact factor: 4.996